A Study of Ketamine in Patients With Treatment-resistant Depression

Double-blind, randomized, parallel-group Phase II trial comparing intravenous ketamine 0.50 mg/kg administered two or three times per week versus matching placebo over a 4-week double-blind treatment phase (Day 1 to Day 29).

Each patient undergoes screening up to 4 weeks, a 4-week double-blind treatment period and a 3-week post-treatment follow-up; key outcomes include antidepressant response and safety/tolerability. Patients were inpatient or agreed to be admitted on dosing days.